Evommune EVMN
NYSE EVMN
$8.31 -0.08 (-0.95%)
As of: Sep 29, 2026 · 3:59 PM EDT

Evommune (EVMN) Net Margin (2025)

Updated

Evommune's Net Margin was -529.77% in FY2025, up 424.63 percentage points from -954.40% in FY2024.

Analysis

Evommune (EVMN) Net Margin (2025) Analysis & Trends

  • Per Business Quant data, Net Margin in earlier years was -954.40% in FY2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 21.86%
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 21.27%
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn -8.04%
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn 22.61%
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 18.81%
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 23.62%
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn -134.51%
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn -1.65%
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 32.99%
10 Evommune 304.40 Mn -333.11 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 -124.75%
Mar 31, 2025 -485.23%
API Access

Evommune Net Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-margin&ticker=EVMN&period=max&api_key=YOUR_API_KEY